Alcobra Ltd. (NASDAQ:ADHD) has received a consensus recommendation of “Hold” from the ten ratings firms that are covering the company, MarketBeat reports. Two equities research analysts have rated the stock with a sell recommendation, seven have issued a hold recommendation and one has issued a buy recommendation on the company. The average 12-month target price among brokers that have covered the stock in the last year is $2.02.

ADHD has been the topic of a number of recent analyst reports. Zacks Investment Research raised Alcobra from a “hold” rating to a “buy” rating and set a $1.25 price target on the stock in a report on Friday, June 2nd. Roth Capital set a $4.00 price target on Alcobra and gave the company a “buy” rating in a report on Wednesday, May 31st. Jefferies Group LLC reaffirmed a “hold” rating and set a $1.25 price target on shares of Alcobra in a report on Monday, June 12th. Finally, ValuEngine cut Alcobra from a “sell” rating to a “strong sell” rating in a report on Friday, June 2nd.

Alcobra (NASDAQ ADHD) opened at 1.11 on Tuesday. The firm’s 50-day moving average price is $1.05 and its 200 day moving average price is $1.13. Alcobra has a 52-week low of $0.83 and a 52-week high of $4.93. The firm’s market cap is $30.59 million.

Alcobra (NASDAQ:ADHD) last released its quarterly earnings results on Friday, August 11th. The biotechnology company reported ($0.13) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.15) by $0.02. On average, equities analysts anticipate that Alcobra will post ($0.50) earnings per share for the current year.

TRADEMARK VIOLATION NOTICE: This article was first posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this article on another publication, it was copied illegally and reposted in violation of US and international copyright laws. The original version of this article can be read at https://www.thecerbatgem.com/2017/09/12/alcobra-ltd-adhd-receives-consensus-recommendation-of-hold-from-brokerages.html.

Large investors have recently made changes to their positions in the stock. Citadel Advisors LLC raised its holdings in Alcobra by 7,251.0% during the first quarter. Citadel Advisors LLC now owns 100,114 shares of the biotechnology company’s stock worth $114,000 after purchasing an additional 101,514 shares in the last quarter. Worth Venture Partners LLC bought a new stake in Alcobra during the first quarter worth approximately $229,000. Finally, Royce & Associates LP raised its holdings in Alcobra by 15.5% during the first quarter. Royce & Associates LP now owns 745,055 shares of the biotechnology company’s stock worth $849,000 after purchasing an additional 100,000 shares in the last quarter. 29.68% of the stock is currently owned by hedge funds and other institutional investors.

About Alcobra

Alcobra Ltd is a development-stage biopharmaceutical company. The Company is focused on development and commercialization of its lead product candidates, including MDX and ADAIR. MDX is a oral drug, for the treatment of ADHD and other cognitive disorders, including Fragile X. MDX is a combined rapid onset ER formulation of the chemical pyridoxine pyroglutamate, which is more commonly known as metadoxine.

Analyst Recommendations for Alcobra (NASDAQ:ADHD)

Receive News & Stock Ratings for Alcobra Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alcobra Ltd. and related stocks with our FREE daily email newsletter.